Effectiveness and safety of antiviral or antibody treatments for Coronavirus
[sidebar]
Commissioner: Infectious Disease Prevention and Control Branch of the Public Health Agency of Canada (PHAC)
Funder: Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)
Share Buttons [span][/span]
[ssba-buttons] [/sidebar] [sidebar-content]- The results of this rapid review will used by the Infectious Disease Prevention and Control Branch of the Public Health Agency of Canada (PHAC) for guidance on the treatment of novel coronavirus (COVID-19)
- Current evidence for the effectiveness of antiviral therapies for coronavirus is not conclusive and suffers from a lack of well-designed prospective trials or observational studies
- None of the interventions in this review can be recommended for use in patients with coronavirus
- Existing body of evidence is weighted heavily towards ribavirin (41/54 studies), which has not shown conclusive evidence of effectiveness. Future investigations may benefit from focusing on other potential candidates for antiviral therapy
Related Projects:
Category : KS Projects
Date : 27 Apr 2020